{
    "clinical_study": {
        "@rank": "117775", 
        "acronym": "IoxRea", 
        "arm_group": {
            "arm_group_label": "Iohexol", 
            "arm_group_type": "Experimental", 
            "description": "injection of 5 ml of iohexol"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to assess the feasibility of estimating the clearance of\n      iohexol as an indirect measure of glomerular filtration rate in patients with unstable renal\n      function in the intensive care unit through analysis of rich iohexol plasma kinetics."
        }, 
        "brief_title": "Measuring the Plasma Clearance of Iohexol to Estimate Glomerular Filtration Rate in Intensive Care Unit Patients: Preliminary Feasibility Study", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Circulatory Failure", 
        "condition_browse": {
            "mesh_term": "Shock"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 18 years\n\n          -  Patient admitted to intensive care for less than 12 hours\n\n          -  Acute circulatory failure\n\n          -  Patient carrying an arterial catheter\n\n          -  Informed consent obtained\n\n          -  Affiliated to social security system\n\n        Exclusion Criteria:\n\n          -  Administration of iohexol the week before intensive care admission\n\n          -  Administration of iohexol expected within 24 hours of study entry\n\n          -  Known history of cutaneous immediate or delayed allergic reaction to the injection of\n             the product\n\n          -  Indication for albumin transfusion within 24 hours of potential inclusion in the\n             study\n\n          -  Pregnancy or breastfeeding in progress\n\n          -  Patient under guardianship or judicial protection known at the time of inclusion\n\n          -  Withdrawal of consent\n\n          -  Administration of iohexol outside the study within 24 hours after administration of\n             iohexol in the context of the study\n\n          -  Administration of intravenous albumin in the 24 hours following administration of\n             iohexol in the context of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02050269", 
            "org_study_id": "PHAO13-SE / IoxRea", 
            "secondary_id": [
                "2013-003936-65", 
                "2013-R49", 
                "131229A-11"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Iohexol", 
            "description": "Iohexol, 300 mg/mL", 
            "intervention_name": "Iohexol", 
            "intervention_type": "Drug", 
            "other_name": "Iohexol"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 28, 2014", 
        "location": {
            "contact": {
                "last_name": "Stephan EHRMANN, MCU-PH"
            }, 
            "facility": {
                "address": {
                    "city": "Tours", 
                    "country": "France", 
                    "zip": "37044"
                }, 
                "name": "Service de R\u00e9animation Polyvalente, CHRU de Tours"
            }, 
            "investigator": {
                "last_name": "Stephan EHRMANN, MCU-PH", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Measuring the Plasma Clearance of Iohexol to Estimate Glomerular Filtration Rate in Intensive Care Unit Patients: Preliminary Feasibility Study", 
        "overall_contact": {
            "email": "stephanehrmann@gmail.com", 
            "last_name": "Stephan EHRMANN, MCU-PH", 
            "phone": "+33(0)2.47.47.98.51"
        }, 
        "overall_contact_backup": {
            "email": "marie.coudray@med.univ-tours.fr", 
            "last_name": "Marie COUDRAY", 
            "phone": "+33(0)2.47.47.46.64"
        }, 
        "overall_official": {
            "affiliation": "University Hospital, Tours", 
            "last_name": "Stephan EHRMANN, MCU-PH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: ANSM - Agence national de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Plasma clearance of iohexol", 
            "safety_issue": "No", 
            "time_frame": "24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02050269"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Plasma clearance of iohexol in patients developping or not acute kidney injury", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Link between plasma iohexol clearance and kindney injury markers", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "measure": "Link between injury and/or functional kidney dammage and subsequent acute kidney injury", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Link between plasma iohexol clearance and urinary metabolomic markers", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "measure": "Comparaison of plasma iohexol clearance measured with 3 and 6 vs. 9 kinetic points", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }
        ], 
        "source": "University Hospital, Tours", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Tours", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}